Selected References:

  • Auyeung-Kima DJ, et al. 2009. Developmental and peripostnatal study in cynomolgus monkeys with belimumab, a monoclonal antibody directed against B-lymphocyte stimulator. Reproductive Toxicology; 28:443-455.
  • Beaulieu DB, et al. 2018. Use of biologic therapy by pregnant women with inflammatory bowel disease does not affect infant response to vaccines. Clin. Gastroenterol. Hepatol. 16, 99–105.
  • Benlysta® Prescribing Information. Available online at https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Benlysta/pdf/BENLYSTA-PI-MG-IFU-COMBINED.PDF. Updated August 1, 2018.
  • Julsgaard M, et al. 2016. Concentrations of adalimumab and infliximab in mothers and newborns, and effects on infection. Gastroenterology, 151:110-119.
  • Kathpalia P, et al. 2016. Detectable drug levels in infants exposed to biologics: so what? Gastroenterology. 151:25–6.
  • Martin Bortlik, et al. 2014. Impact of Anti–Tumor Necrosis Factor Alpha Antibodies Administered to Pregnant Women With Inflammatory Bowel Disease on Long-term Outcome of Exposed Children, Inflammatory Bowel Diseases. 20(3):495–501.
  • Miller RK, et al. 2014. ABSTRACT. Preliminary Data from the Belimumab Pregnancy Registry: International Prospective Cohort Study of Pregnancy Outcomes. OTIS/ENTIS meeting, Toronto, Can.
  • Peart E, Clowse MEB. 2014. Systemic lupus erythematosus and pregnancy outcomes: an update and review of the literature. Curr Opin Rheumatol; 26:118-123.
  • Sandhu VK, et al. 2015. Monoclonal Antibodies, Systemic Lupus erythematosus, and Pregnancy. J Rheumatol; 42:728-730.